ELEVANCE HEALTH, INC.
(In Millions, Except Per Share Data or as Otherwise Stated Herein)
This Management's Discussion and Analysis of Financial Condition and Results of
Operations ("MD&A") should be read in conjunction with the accompanying
consolidated financial statements and notes, our consolidated financial
statements and notes as of and for the year ended December 31, 2020 and the MD&A
included in our 2020 Annual Report on Form 10-K. References to the terms "we,"
"our," "us," or "Anthem" used throughout this MD&A refer to Anthem, Inc. , an
Indiana corporation, and unless the context otherwise requires, its direct and
indirect subsidiaries. References to the "states" include the District of
Columbia and Puerto Rico , unless the context otherwise requires.
Results of operations, cost of care trends, investment yields and other measures
for the three and nine months ended September 30, 2021 are not necessarily
indicative of the results and trends that may be expected for the full year
ending December 31, 2021 , or any other period.
Overview
We are one of the largest health benefits companies in the United States in
terms of medical membership, serving approximately 45 medical members through
our affiliated health plans as of September 30, 2021 . We are an independent
licensee of the Blue Cross and Blue Shield Association ("BCBSA"), an association
of independent health benefit plans. We serve our members as the Blue Cross
licensee for California and as the Blue Cross and Blue Shield ("BCBS") licensee
for Colorado , Connecticut , Georgia , Indiana , Kentucky , Maine , Missouri
(excluding 30 counties in the Kansas City area), Nevada , New Hampshire , New York
(in the New York City metropolitan area and upstate New York ), Ohio , Virginia
(excluding the Northern Virginia suburbs of Washington, D.C. ) and Wisconsin . In
a majority of these service areas, we do business as Anthem Blue Cross , Anthem
Blue Cross and Blue Shield , and Empire Blue Cross Blue Shield or Empire Blue
Cross . We also conduct business through arrangements with other BCBS licensees
as well as other strategic partners. Through our subsidiaries, we also serve
customers in numerous states and Puerto Rico as AIM Specialty Health ,
Amerigroup, Aspire Health , Beacon, CareMore , Freedom Health , HealthLink,
HealthSun, MMM, Optimum HealthCare , Simply Healthcare , and/or UniCare. Pharmacy
benefits management ("PBM") services are offered through our IngenioRx
subsidiary. We are licensed to conduct insurance operations in all fifty states,
the District of Columbia and Puerto Rico through our subsidiaries.
For additional information about our organization, see Part I, Item 1,
"Business" and Part II, Item 7, "Management's Discussion and Analysis of
Financial Condition and Results of Operations," included in our 2020 Annual
Report on Form 10-K. Additional information on our segments can be found in this
MD&A and in Note 15, "Segment Information" of the Notes to Consolidated
Financial Statements included in Part I, Item 1 of this Form 10-Q.
COVID-19
The COVID-19 pandemic continues to impact the global economy, cause market
instability and put pressure on the healthcare system, and it has impacted, and
will likely continue to impact, our membership, our benefit expense and our
members' behavior, including how members access healthcare. We continue to
assist our customers, providers, members and communities in addressing the
effects of the COVID-19 pandemic, including by providing expanded benefit
coverage for COVID-19 diagnostic tests, treatment and vaccine administration and
taking steps to increase vaccinations by enabling, educating, and encouraging
vaccine acceptance among our members as well as in the communities in which we
operate.
COVID-19 care, testing and vaccine administration, and the impact of new
COVID-19 variants, have resulted in increased medical costs for us in 2021.
Since June 30, 2020 , our Medicaid membership has grown as a result of the
temporary suspension of eligibility recertification in response to the COVID-19
pandemic, which will remain suspended at least until the first quarter of 2022.
Our Commercial fee-based membership has decreased in this same period due to
in-group attrition likely attributable to the COVID-19 pandemic. See "Business
Trends - Medical Cost Trends" below for a discussion of the impact of COVID-19
on our healthcare costs.
The COVID-19 pandemic continues to evolve and the full extent of its impact will
depend on future developments, which are highly uncertain and cannot be
predicted at this time. We will continue to monitor the COVID-19 pandemic as
well
-44-
--------------------------------------------------------------------------------
as resulting legislative and regulatory changes to manage our response and assess and mitigate potential adverse impacts to our business. For additional discussion related to the COVID-19 pandemic and our risk factors, see Part I, Item 1, "Business-COVID-19", Part I, Item 1A, "Risk Factors" and Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations-COVID-19" included in our 2020 Annual Report on Form 10-K. Business Trends The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended (collectively, the "ACA") has changed and may continue to make broad-based changes to theU.S. healthcare system. InJune 2021 , theU.S. Supreme Court issued its opinion and dismissed the latest legal challenge to the constitutionality of the ACA, leaving the law intact. We expect the ACA will continue to impact our business model and strategy. In 2020, we made the decision to modestly expand our participation in the Individual ACA-compliant market for 2021. Our strategy has been, and will continue to be, to only participate in rating regions where we have an appropriate level of confidence that these markets are on a path toward sustainability, including, but not limited to, factors such as expected financial performance, regulatory environment, and underlying market characteristics. We currently offer Individual ACA-compliant products in 103 of the 143 rating regions in which we operate. In addition, the continuing growth in our government-sponsored business exposes us to increased regulatory oversight. Our IngenioRx subsidiary markets and offers PBM services to our affiliated health plan customers throughout the country, as well as to customers outside of the health plans we own. Our comprehensive PBM services portfolio includes services such as formulary management, pharmacy networks, a prescription drug database, member services and mail order capabilities. IngenioRx delegates certain PBM administrative functions, such as claims processing and prescription fulfillment, toCaremarkPCS Health, L.L.C. , which is a subsidiary of CVS Health Corporation, pursuant to a five-year agreement. With IngenioRx, we retain the responsibilities for clinical and formulary strategy and development, member and employer experiences, operations, sales, marketing, account management and retail network strategy. Pricing Trends: We strive to price our healthcare benefit products consistent with anticipated underlying medical cost trends. We continue to closely monitor the COVID-19 pandemic (including new COVID-19 variants, which may be more contagious or severe, or less responsive to treatment or vaccines) and the impacts it may have on our pricing, such as surges in COVID-19 related hospitalizations, infection rates, the cost of COVID-19 vaccines and the return of non-COVID-19 healthcare utilization to our estimate of normal levels, based on historical utilization patterns. We frequently make adjustments to respond to legislative and regulatory changes as well as pricing and other actions taken by existing competitors and new market entrants. Product pricing in our Commercial & Specialty Business segment, including ourIndividual and Small Group lines of business, remains competitive. Revenues from the Medicare and Medicaid programs are dependent, in whole or in part, upon annual funding from the federal government and/or applicable state governments. The ACA imposed an annual Health Insurance Provider Fee ("HIP Fee") on health insurers that write certain types of health insurance onU.S. risks. When applicable, we priced our affected products to cover the impact of the HIP Fee, including during 2020. The HIP Fee has been permanently repealed beginning in 2021. Medical Cost Trends: Our medical cost trends are primarily driven by increases in the utilization of services across all provider types and the unit cost increases of these services. We work to mitigate these trends through various medical management programs such as utilization management, condition management, program integrity and specialty pharmacy management, as well as benefit design changes. There are many drivers of medical cost trends that can cause variance from our estimates, such as changes in the level and mix of services utilized, regulatory changes, aging of the population, health status and other demographic characteristics of our members, epidemics, pandemics, advances in medical technology, new high cost prescription drugs, and healthcare provider or member fraud. The COVID-19 pandemic initially caused a decrease in utilization of non-COVID-19 health services, which decreased our claim costs in 2020. Over the course of the first half of 2021, our non-COVID-19 healthcare utilization experience gradually increased toward normalized levels, while COVID-19 related healthcare expenses declined and COVID-19 vaccination administration costs increased. During the third quarter of 2021, theCOVID-19 Delta variant caused a significant increase in COVID-19 related healthcare utilization as a result of increased testing, treatment, and hospitalization costs, which was partially offset by a reduction in non-COVID-19 healthcare utilization. The reduction in non-COVID-19 healthcare utilization was particularly notable in the inpatient setting, as some regions limited elective surgeries in order to preserve limited resources to treat patients hospitalized with COVID-19. -45-
--------------------------------------------------------------------------------
Our expenses in 2020 and the first nine months of 2021 included additional costs to cover COVID-19 related testing, treatment and vaccine administration. In the fourth quarter of 2021, we expect COVID-19 related healthcare expenses to decline from the surge experienced during the third quarter of 2021 related to the Delta variant and utilization of non-COVID-19 healthcare services to recover toward the levels experienced in 2021 prior to the Delta surge. We anticipate additional COVID-19 vaccination costs as young children become eligible for the vaccine and more adults choose to receive the vaccine and booster doses. Further increases and pent-up demand in the utilization of non-COVID-19 healthcare services, as well as increases in acuity associated with deferred services and the long-term health complications of COVID-19, may increase our claim costs in the future and affect our medical cost trends. We continue to monitor the COVID-19 pandemic and its impacts on our business, financial condition, results of operations and medical cost trends. For additional discussion regarding business trends, see Part I, Item 1, "Business" included in our 2020 Annual Report on Form 10-K. Regulatory Trends and Uncertainties Federal and state governments have enacted, and may continue to enact, legislation and regulations in response to the COVID-19 pandemic that have had, and we expect will continue to have, a significant impact on healthcare benefits, consumer eligibility for public programs and our cash flows for all of our lines of business. These actions, which are or have been in effect for various durations, provide, among other things: •waivers on cost-sharing on COVID-19 testing, treatment, vaccines and related services; •reforms, including waiving Medicare originating site restrictions for qualified providers providing telehealth services; •financial support to healthcare providers, including expansion of the Medicare accelerated payment program to all providers receiving Medicare payments; •mandated expansion of premium payment terms, including the time period for which claims can be denied for lack of payment; and •mandates related to prior authorizations and payment levels to providers, additional consumer enrollment windows and an increased ability to provide telehealth services. The Consolidated Appropriations Act of 2021, which was enacted inDecember 2020 (the "Appropriations Act"), contains a number of provisions that may have a material effect upon our business, including procedures and coverage requirements related to surprise medical bills and new mandates for continuity of care for certain patients, price comparison tools, disclosure of broker compensation and reporting on pharmacy benefits and drug costs. The health plan-related requirements of the Appropriations Act have varying effective dates beginning as early asDecember 2021 , some of which have been extended since the enactment of the Appropriations Act. The American Rescue Plan Act of 2021, (the "Rescue Plan"), which was enacted inMarch 2021 , contains several health-related provisions that have impacted our business, including expansion of premium tax credits for our Individual exchange business and full subsidization of the Consolidated Omnibus Budget Reconciliation Act ("COBRA") continuation coverage for those who were involuntarily terminated or had their work hours reduced. The Rescue Plan's premium tax provisions became effective inJanuary 2021 , while the COBRA premium subsidization extended from April throughSeptember 2021 . The ACA presented us with new growth opportunities, but also introduced new risks, regulatory challenges and uncertainties, and required changes in the way products are designed, underwritten, priced, distributed and administered. Changes to our business environment are likely to continue as elected officials at the national and state levels continue to enact, and both elected officials and candidates for election continue to propose, significant modifications to existing laws and regulations, including changes to taxes and fees. We will continue to evaluate the impact of the ACA as any further developments or judicial rulings occur. For additional discussion regarding regulatory trends and uncertainties and risk factors, see Part I, Item 1, "Business - Regulation", Part I, Item 1A, "Risk Factors", and the "Regulatory Trends and Uncertainties" section of Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in our 2020 Annual Report on Form 10-K. -46-
--------------------------------------------------------------------------------
Other Significant Items Business and Operational Matters OnJune 29, 2021 , we completed our acquisition ofMMM Holdings, LLC ("MMM") and its Medicare Advantage plan, Medicaid plan and other affiliated companies fromInnovaCare Health, L.P. MMM is aPuerto Rico -based integrated healthcare organization and seeks to provide its Medicare Advantage and Medicaid members with a whole health experience through its network of specialized clinics and wholly owned independent physician associations. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve. OnApril 28, 2021 , we completed our acquisition of myNEXUS, Inc. ("myNEXUS") fromWindRose Health Investors . myNEXUS is a comprehensive home-based nursing management company for payors and, at the time of acquisition, delivered integrated clinical support services for Medicare Advantage members across twenty states. This acquisition aligns with our strategy to manage integrated, whole person multi-site care and support by providing national, large-scale expertise to manage nursing services in the home and facilitate transitions of care. OnFebruary 28, 2020 , we completed our acquisition ofBeacon Health Options, Inc. ("Beacon"), the largest independently held behavioral health organization in the country. At the time of acquisition, Beacon served more than thirty-four million individuals across all fifty states. This acquisition aligned with our strategy to diversify into health services and deliver both integrated solutions and care delivery models that personalize care for people with complex and chronic conditions. For additional information, see Note 3, "Business Acquisitions," of the Notes to Consolidated Financial Statements included in Part 1, Item 1 of this Form 10-Q. In 2020, we introduced enterprise-wide initiatives to optimize our business, and as a result, recorded a charge of$653 in selling, general and administrative expenses for the year endedDecember 31, 2020 . We believe these initiatives largely represent the next step forward in our progression towards becoming a more agile organization, including process automation and a reduction in our office space footprint. For additional information see Note 4, "Business Optimization Initiatives" and Note 16, "Leases" of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q. Litigation Matters In the consolidated multi-district proceeding in theUnited States District Court for the Northern District of Alabama (the "Court") captioned In re Blue Cross Blue Shield Antitrust Litigation ("BCBSA Litigation"), the BCBSA andBlue Cross and/orBlue Shield licensees, including us (the "Blue plans"), have approved a settlement agreement and release (the "Subscriber Settlement Agreement") with the plaintiffs representing a putative nationwide class of health plan subscribers. Generally, the lawsuits in the BCBSA Litigation challenge elements of the licensing agreements between the BCBSA and the independently owned and operated Blue plans. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers, and the Subscriber Settlement Agreement applies only to the putative subscriber class. No settlement agreement has been reached with the provider plaintiffs at this time, and the defendants continue to contest the consolidated cases brought by the provider plaintiffs. If approved by the Court, the Subscriber Settlement Agreement will require the defendants to make a monetary settlement payment, our portion of which is estimated to be$594 , and will include certain non-monetary terms. As ofSeptember 30, 2021 , the liability balance accrued for our estimated remaining payment obligation was$507 , net of payments made. All terms of the Subscriber Settlement Agreement are subject to approval by the Court before they become effective. For additional information regarding the BCBSA Litigation, see Note 11, "Commitments and Contingencies - Litigation and Regulatory Proceedings - Blue Cross Blue Shield Antitrust Litigation," of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q. InJanuary 2019 , we exercised our contractual right to terminate our PBM agreement (the "ESI PBM Agreement") withExpress Scripts, Inc. ("Express Scripts"). We completed the transition of our members from Express Scripts to IngenioRx byJanuary 1, 2020 . Notwithstanding our termination of the ESI PBM Agreement, the litigation between us and Express Scripts regarding the ESI PBM Agreement continues. For additional information regarding this lawsuit, see Note 11, "Commitments -47-
--------------------------------------------------------------------------------
and Contingencies - Litigation and Regulatory Proceedings -Express Scripts, Inc. Pharmacy Benefit Management Litigation," of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q. Selected Operating Performance For the twelve months endedSeptember 30, 2021 , total medical membership increased 2.4, or 5.7%. Our medical membership grew in both our Government Business and Commercial & Specialty Business segments. The increase in our Government Business membership was primarily driven by increases in our Medicaid membership, including organic growth resulting from the temporary suspension of eligibility recertification during the COVID-19 pandemic, which will remain suspended at least until the first quarter of 2022, our acquisition of MMM onJune 29, 2021 , the launch of our HealthyBlue managed care alliance inNorth Carolina and organic growth in our Medicare Advantage business. Commercial & Specialty Business membership growth included increases in Group risk-based membership resulting from sales exceeding lapses and increases in Individual membership due to the ACA expansion in 2021, partially offset by declines in Group fee-based membership due to in-group attrition likely resulting from the COVID-19 pandemic. Operating revenue for the three months endedSeptember 30, 2021 was$35,548 , an increase of$4,899 , or 16.0%, from the three months endedSeptember 30, 2020 . The increase in operating revenue for the three months endedSeptember 30, 2021 compared to 2020 was primarily driven by higher premium revenue due mainly to membership growth in our Government Business segment, including related to our acquisition of MMM, and increased product revenue in our IngenioRx segment. These increases were partially offset by the impact of lower premium revenue associated with the repeal of the HIP Fee for 2021. Operating revenue for the nine months endedSeptember 30, 2021 was$100,925 , an increase of$11,650 , or 13.0%, from the nine months endedSeptember 30, 2020 . The increase in operating revenue for the nine months endedSeptember 30, 2021 compared to 2020 was primarily driven by higher premium revenue due mainly to membership growth in our Government Business segment, including related to the acquisition of MMM, increased product revenue in our IngenioRx segment and premium rate increases in our Commercial & Specialty Business segment. These increases were partially offset by the impact of lower premium revenue associated with the repeal of the HIP Fee for 2021. Net income for the three months endedSeptember 30, 2021 was$1,502 , an increase of$1,280 , or 576.6%, from the three months endedSeptember 30, 2020 . The increase in net income for the three months endedSeptember 30, 2021 was primarily due to increased operating gain in all of our business segments, primarily the result of the absence of charges in 2021 for our business optimization initiatives and the BCBSA litigation accrual recognized during the third quarter of 2020. Net income for the nine months endedSeptember 30, 2021 was$4,970 , an increase of$949 , or 23.6% from the nine months endedSeptember 30, 2020 . The increase in net income for the nine months endedSeptember 30, 2021 was primarily due to increased operating gain in all of our business segments, primarily due to the absence of charges in 2021 for our business optimization initiatives and the BCBSA litigation accrual recognized during the third quarter of 2020. These operating gain increases were partially offset by increased COVID-19 and non-COVID-19 healthcare costs. Our fully-diluted shareholders' earnings per share ("EPS") was$6.13 for the three months endedSeptember 30, 2021 , which represented a 604.6% increase from EPS of$0.87 for the three months endedSeptember 30, 2020 . Our fully-diluted shareholders' EPS was$20.09 for the nine months endedSeptember 30, 2021 , which represented a 27.6% increase from fully-diluted EPS of$15.75 for the nine months endedSeptember 30, 2020 . The increase in EPS for the three and nine months endedSeptember 30, 2021 compared to 2020 resulted primarily from the increase in net income, as well as lower shares outstanding in 2021. Operating cash flow for the nine months endedSeptember 30, 2021 and 2020 was$6,692 and$6,875 , respectively. The decrease in operating cash flow was primarily driven by the timing of working capital changes, partially offset by higher net income in 2021. -48-
--------------------------------------------------------------------------------
Membership
In the first quarter of 2021, we updated our medical membership reporting to better align with how we view our business. Our medical membership now includes the following customer types:Individual, Group risk-based, Group fee-based, BlueCard®, Medicare, Medicaid and our Federal Employees Health Benefits ("FEHB") Program. BCBS-branded business generally refers to members in our service areas licensed by the BCBSA. Non-BCBS-branded business refers to members in our non-BCBS-branded Amerigroup,Freedom Health , HealthSun, MMM,Optimum HealthCare and Simply Healthcare plans, as well as HealthLink and UniCare members. In addition to the above medical membership, we also serve customers who purchase one or more of our other products or services that are often ancillary to our health business. •Individual consists of individual customers under age 65 and their covered dependents. Individual policies are generally sold through independent agents and brokers, retail partnerships, our in-house sales force or via the exchanges. Individual business is sold on a risked-based basis. We offer on-exchange products through public exchanges and off-exchange products. Federal premium subsidies are available only for certain public exchange Individual products. Unsubsidized Individual customers are generally more sensitive to product pricing and, to a lesser extent, the configuration of the network and the efficiency of administration. Customer turnover is generally higher with Individual as compared to Group risk-based business. •Group risk-based consists of employer customers who purchase products on a full-risk basis, which are products for which we charge a premium and indemnify our policyholders against costs for health benefits. Group risk-based accounts include Local Group customers and National Accounts. Local Group consists of those employer customers with less than 5% of eligible employees located outside of the headquarter state, as well as customers with more than 5% of eligible employees located outside of the headquarter state with up to 5,000 eligible employees. In addition, Local Group includesStudent Health members. National Accounts generally consist of multi-state employer groups primarily headquartered in anAnthem service area with at least 5% of the eligible employees located outside of the headquarter state and with more than 5,000 eligible employees. Some exceptions are allowed based on broker and consultant relationships. Group risk-based accounts are generally sold through brokers or consultants who work with industry specialists from our in-house sales force and are offered both on and off the public exchanges. •Group fee-based customers represent employer groups, Local Group, including UniCare members, and National Accounts, who purchase fee-based products and elect to retain most or all of the financial risk associated with their employees' healthcare costs. Some fee-based customers choose to purchase stop loss coverage to limit their retained risk. Group fee-based accounts are generally sold through independent brokers or consultants retained by the customer working with our in-house sales force. •BlueCard® host customers represent enrollees ofBlue Cross and/orBlue Shield plans not owned byAnthem who receive healthcare services in our BCBSA licensed markets. BlueCard® membership consists of estimated host members using the national BlueCard® program. Host members are generally members who reside in or travel to a state in which anAnthem subsidiary is theBlue Cross and/orBlue Shield licensee and who are covered under an employer-sponsored health plan issued by a non-Anthem controlled BCBSA licensee (the "home Blue plan"). We perform certain functions, including claims pricing and administration, for BlueCard® members, for which we receive administrative fees from the BlueCard® members' home Blue plans. Other administrative functions, including maintenance of enrollment information and customer service, are performed by the home Blue plan. Host members are computed using, among other things, the average number of BlueCard® claims received per month. •Medicare customers are Medicare-eligible individual members age 65 and over who have enrolled in Medicare Supplement plans; Medicare Advantage, including Special Needs Plans ("SNPs"), also known as Medicare Advantage SNPs; Medicare Part D; and dual-eligible programs through Medicare-Medicaid Plans ("MMPs"). Medicare Supplement plans typically pay the difference between healthcare costs incurred by a beneficiary and amounts paid by Medicare. Medicare Advantage plans provide Medicare beneficiaries with a managed care alternative to traditional Medicare and often include a Medicare Part D benefit. In addition, our Medicare Advantage SNPs provide tailored benefits to special needs individuals who are institutionalized or have severe or disabling chronic conditions and to dual-eligible customers, who are low-income seniors and persons under age 65 with disabilities. Medicare Advantage SNPs are coordinated care plans specifically designed to provide targeted care, covering all the healthcare services considered medically necessary for members and often providing professional care coordination services, with personal guidance and programs that help members maintain their health. Medicare Advantage membership also includes Medicare Advantage members in our Group Retiree Solutions business who -49-
--------------------------------------------------------------------------------
are retired members of Commercial accounts or retired members of groups who are
not affiliated with our Commercial accounts who have selected a Medicare
Advantage product through us. Medicare Part D offers a prescription drug plan to
Medicare and MMP beneficiaries. MMP, which was established as a result of the
passage of the ACA, is a demonstration program focused on serving members who
are dually eligible for Medicaid and Medicare. Medicare Supplement and Medicare
Advantage products are marketed in the same manner, primarily through
independent agents and brokers.
•Medicaid membership represents eligible members who receive healthcare benefits
through publicly funded healthcare programs, including Medicaid, ACA-related
Medicaid expansion programs, Temporary Assistance for Needy Families, programs
for seniors and people with disabilities, Children's Health Insurance Programs,
and specialty programs such as those focused on long-term services and support,
HIV/AIDS, foster care, behavioral health and/or substance abuse disorders, and
intellectual disabilities or developmental disabilities, among others.
•FEHB members consist of
September 30
(In thousands) 2021 2020 Change % Change
Medical Membership
Commercial & Specialty Business:
Individual 769 701 68 9.7 %
Group Risk-Based 3,946 3,774 172 4.6 %
Commercial Risk-Based 4,715 4,475 240 5.4 %
BlueCard® 6,166 6,106 60 1.0 %
Group Fee-Based 19,370 19,508 (138) (0.7) %
Commercial Fee-Based 25,536 25,614 (78) (0.3) %
Total Commercial & Specialty Business 30,251 30,089 162 0.5 %
Government Business:
Medicare Advantage 1,853 1,416 437 30.9 %
Medicare Supplement 947 933 14 1.5 %
Total Medicare 2,800 2,349 451 19.2 %
Medicaid 10,391 8,569 1,822 21.3 %
Federal Employees Health Benefits 1,629 1,618 11 0.7 %
Total Government Business 14,820 12,536 2,284 18.2 %
Total Medical Membership 45,071 42,625 2,446 5.7 %
Other Membership
Life and Disability Members 4,695 5,029 (334) (6.6) %
Dental Members 6,637 6,356 281 4.4 %
Dental Administration Members 1,486 1,315 171 13.0 %
Vision Members 7,974 7,487 487 6.5 %
Medicare Part D Standalone Members 438 405 33 8.1 %
Medical Membership Total medical membership increased primarily due to growth in our Government Business, which was driven primarily by increases in our Medicaid membership, including organic growth resulting from the temporary suspension of eligibility
-50-
--------------------------------------------------------------------------------
recertification during the COVID-19 pandemic, growth resulting from our acquisition of MMM onJune 29, 2021 and the launch of our HealthyBlue managed care alliance inNorth Carolina . Our Medicare Advantage membership also increased due to organic growth. Increases in Group risked-based membership resulting from sales exceeding lapses and increases in Individual membership due to our ACA expansion in 2021 also contributed to overall membership increases. Declines in our Group fee-based membership due to in-group attrition likely attributable to the COVID-19 pandemic partially offset the increases in our medical membership. Other Membership Our other membership can be impacted by changes in our medical membership, as our medical members often purchase our other products that are ancillary to our health business. Life and disability membership decreased primarily due to the loss of a Group risked-based account and membership decreases in our Group fee-based business. Dental membership increased primarily due to higher sales in ourIndividual and Group risk-based accounts and growth in our FEHB program. Dental administration membership increased due to growth in our FEHB program. Vision membership increased as a result of growth in our Medicare business. Consolidated Results of Operations Our consolidated summarized results of operations and other financial information for the three and nine months endedSeptember 30, 2021 and 2020 are as follows:
© Edgar Online, source
